Regeneron calls time on Eylea/nesvacumab combo
Regeneron says that a combination of Eylea and nesvacumab being co-developed with Bayer will not move into Phase III testing for two eye conditions following disappointing Phase II data.
Read More
Tag: nesvacumab
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
